Efficacy and Safety of a Novel Topical Minocycline Foam for the Treatment of Moderate-to-Severe Acne Vulgaris: A Phase 3 Study.
FMX101 4% topical minocycline foam, has been demonstrated as an effective and safe treatment for acne vulgaris. Further evaluate the efficacy and safety of FMX101 4% in treating moderate-to-severe AV. A 12-week, multicenter, randomized (1:1), double-blind, vehicle-controlled study was conducted. Co-primary end points were the absolute change in inflammatory lesion count from baseline and the rate of treatment success (IGA score: 0 or 1 with a ≥2-grade improvement). 1488 subjects were in the intent-to-treat population. FMX101 4% group had significantly greater reductions in the number of inflammatory lesions from baseline (P<.0001) and a greater rate of IGA treatment success (P<.0001) vs foam vehicle group at week 12. FMX101 4% was generally safe and well-tolerated. Efficacy and safety of FMX101 4% was not characterized in subjects with mild AV. FMX101 4% topical minocycline foam was effective and safe for the treatment of moderate-to-severe AV.